PHATHOM PHARMACEUTICALS INC
PharmaPHATHOM PHARMACEUTICALS INC is a pharmaceutical company focused on Cardiovascular, Infectious Disease. Key products include VOQUEZNA.
PHATHOM PHARMACEUTICALS INC at a Glance
- Strong track record with 88% execution quality across 13 trials
- Fast trial execution (6 months median completion)
PHATHOM PHARMACEUTICALS INC's Key Drugs
PHATHOM PHARMACEUTICALS INC's core commercial portfolio centers on VOQUEZNA, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
PHATHOM PHARMACEUTICALS INC's Recent FDA Approvals
PHATHOM PHARMACEUTICALS INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
PHATHOM PHARMACEUTICALS INC's Therapeutic Areas
PHATHOM PHARMACEUTICALS INC's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PHATHOM PHARMACEUTICALS INC's Top Competitors
PHATHOM PHARMACEUTICALS INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PHATHOM PHARMACEUTICALS INC Pipeline Snapshot
PHATHOM PHARMACEUTICALS INC has 5 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 1 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VOQUEZNA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 3/3 completed
- • Speed: 6 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-07-17
- Latest
- 2024-07-17
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges